Comparing Aileron Therapeutics (ALRN) and Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ: JUNO) and Aileron Therapeutics (NASDAQ:ALRN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Juno Therapeutics and Aileron Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juno Therapeutics 1 6 8 0 2.47
Aileron Therapeutics 0 0 4 0 3.00

Juno Therapeutics currently has a consensus target price of $46.41, indicating a potential downside of 21.42%. Aileron Therapeutics has a consensus target price of $19.33, indicating a potential upside of 57.18%. Given Aileron Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aileron Therapeutics is more favorable than Juno Therapeutics.

Earnings and Valuation

This table compares Juno Therapeutics and Aileron Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Juno Therapeutics $79.36 million 84.97 -$245.58 million ($3.38) -17.47
Aileron Therapeutics N/A N/A N/A N/A N/A

Aileron Therapeutics has higher revenue, but lower earnings than Juno Therapeutics.

Profitability

This table compares Juno Therapeutics and Aileron Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juno Therapeutics -332.05% -32.54% -24.87%
Aileron Therapeutics N/A N/A N/A

Insider & Institutional Ownership

67.0% of Juno Therapeutics shares are owned by institutional investors. Comparatively, 12.6% of Aileron Therapeutics shares are owned by institutional investors. 15.3% of Juno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aileron Therapeutics beats Juno Therapeutics on 5 of the 9 factors compared between the two stocks.

About Juno Therapeutics

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

About Aileron Therapeutics

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply